Key result
Ranolazine significantly improved diastolic parameters compared to placebo in patients with heart failure with preserved ejection fraction (MD 0.45; 95% CI 27.18-39.50).
Why the study?
This study was conducted to evaluate the efficacy of using ranolazine to improve diastolic performance and exercise capacity in heart failure with preserved ejection fraction.
Does ranolazine improve diastolic performance and exercise capacity in patients with heart failure with preserved ejection fraction?
Meta-Analysis
Does ranolazine improve diastolic performance and exercise capacity in patients with heart failure with preserved ejection fraction?
Ranolazine improves diastolic parameters in HFpEF patients without adversely affecting hemodynamics or QT interval, though it does not significantly improve exercise capacity.
Answers are grounded in this paper and cite their sources.
May improve diastolic function in HFpEF; extends meta-analytic evidence without exercise capacity gains.
This article evaluates the efficacy of using ranolazine to improve diastolic performance and exercise capacity in heart failure with preserved ejection fraction. A comprehensive literature review found eight trials where there are no significant difference in peak O2 (p=0.09) and exercise duration (p=0.18) between ranolazine and placebo. The ranolazine group had significantly higher and better diastolic parameters compared to placebo, with a mean difference of 0.45 (95% CI [27.18-39.50]). There were no significant differences for haemodynamic parameters (blood pressure and heart rate) and electrocardiography (QT interval) between ranolazine and placebo. The review found that ranolazine has good wefficacy to improve diastolic performance among heart failure with preserved ejection fraction patients and it does not affect blood pressure, heart rate and rate of ventricular repolarisation (shortening of the QT interval).
No takes yet. Share an insight, caveat, or question.
Putri et al. (2023) conducted a meta-analysis in Heart failure with preserved ejection fraction. Ranolazine vs. Placebo was evaluated on Diastolic parameters (MD 0.45, 95% CI 27.18-39.50). Ranolazine significantly improved diastolic parameters compared to placebo in patients with heart failure with preserved ejection fraction (MD 0.45; 95% CI 27.18-39.50).
Synapse has enriched 10 related papers. Consider them for comparative context: